Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dolby Laboratories, Inc.DLB · Entity 2518 | Director · President and CEO | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dolby Laboratories, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | Direct | 145,252 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Gift · Disposed 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | IndirectBy a trust | 145,252 |
Reported balance
After 2026-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-05 · Gift · Acquired 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
Filing footnotes · ownership attribution and instrument terms
F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5.
F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter.
F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2023 Filed Sep 14, 2023 19:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 1,349 | $83.31 | $112,384.65 |
DisclosureSEC source: 0001209191-23-049516 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,879 F2 · price: The shares were sold in multiple transactions at prices ranging from $83.11 to $83.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 19:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 16,711 | $82.56 | $1,379,735.36 |
DisclosureSEC source: 0001209191-23-049516 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 53,228 F1 · price: The shares were sold in multiple transactions at prices ranging from $82.10 to $83.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 19:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 18,060 | $42.98 | $776,218.80 |
DisclosureSEC source: 0001209191-23-049516 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 69,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2023 Filed Jul 13, 2023 16:54 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 27,090 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-23-042227 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 90,546 Underlying: Class A Common Stock · 27,090 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. The option exercised in this transaction was fully vested and exercisable as of the transaction date. Read SEC document |
| July 13, 2023 Filed Jul 13, 2023 16:54 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 27,090 | $90.00 | $2,438,100.00 |
DisclosureSEC source: 0001209191-23-042227 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,879 Read SEC document |
| July 13, 2023 Filed Jul 13, 2023 16:54 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 27,090 | $42.98 | $1,164,328.20 |
DisclosureSEC source: 0001209191-23-042227 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 78,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 16:54 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 18,060 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-23-042227 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 117,636 Underlying: Class A Common Stock · 18,060 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. The option exercised in this transaction was fully vested and exercisable as of the transaction date. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 16:54 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 18,060 | $87.83 | $1,586,294.68 |
DisclosureSEC source: 0001209191-23-042227 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,879 F1 · price: The shares were sold in multiple transactions at prices ranging from $87.48 to $88.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 16:54 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 18,060 | $42.98 | $776,218.80 |
DisclosureSEC source: 0001209191-23-042227 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 69,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 16:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 27,090 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-23-037387 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 135,696 Underlying: Class A Common Stock · 27,090 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. The option exercised in this transaction was fully vested and exercisable as of the transaction date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 16:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 27,090 | $84.83 | $2,298,085.34 |
DisclosureSEC source: 0001209191-23-037387 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,879 F1 · price: The shares were sold in multiple transactions at prices ranging from $84.19 to $85.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 16:47 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 27,090 | $42.98 | $1,164,328.20 |
DisclosureSEC source: 0001209191-23-037387 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 78,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2023 Filed May 18, 2023 19:27 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,030 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-23-030821 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 162,786 Underlying: Class A Common Stock · 9,030 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. The option exercised in this transaction was fully vested and exercisable as of the transaction date. Read SEC document |
| May 16, 2023 Filed May 18, 2023 19:27 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 9,030 | $83.65 | $755,351.37 |
DisclosureSEC source: 0001209191-23-030821 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,879 F1 · price: The shares were sold in multiple transactions at prices ranging from $83.24 to $84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 16, 2023 Filed May 18, 2023 19:27 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 9,030 | $42.98 | $388,109.40 |
DisclosureSEC source: 0001209191-23-030821 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 60,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 16:56 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,779 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-23-024224 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 0 Underlying: Class A Common Stock · 30,779 shares Expires 2023-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This performance-based stock option award was granted for a total of 97,199 shares of Class A Common Stock at target. The number of shares actually earned and vested upon the achievement of total shareholder return performance criteria measured during a three-year performance period ended on December 15, 2019 was at 95% of target, or 92,339 shares. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 16:56 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 30,779 | $84.44 | $2,598,831.02 |
DisclosureSEC source: 0001209191-23-024224 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,879 F1 · price: The shares were sold in multiple transactions at prices ranging from $84.075 to $84.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 16:56 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 30,779 | $45.50 | $1,400,444.50 |
DisclosureSEC source: 0001209191-23-024224 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 82,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:21 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,780 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-23-019290 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 30,779 Underlying: Class A Common Stock · 30,780 shares Expires 2023-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This performance-based stock option award was granted for a total of 97,199 shares of Class A Common Stock at target. The number of shares actually earned and vested upon the achievement of total shareholder return performance criteria measured during a three-year performance period ended on December 15, 2019 was at 95% of target, or 92,339 shares. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:21 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 4,405 | $81.53 | $359,139.21 |
DisclosureSEC source: 0001209191-23-019290 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,879 F2 · price: The shares were sold in multiple transactions at prices ranging from $81.48 to $81.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:21 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 26,375 | $81.04 | $2,137,517.04 |
DisclosureSEC source: 0001209191-23-019290 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 56,284 F1 · price: The shares were sold in multiple transactions at prices ranging from $80.48 to $81.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:21 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 30,780 | $45.50 | $1,400,490.00 |
DisclosureSEC source: 0001209191-23-019290 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 82,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 18:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,780 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-23-009875 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 61,559 Underlying: Class A Common Stock · 30,780 shares Expires 2023-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This performance-based stock option award was granted for a total of 97,199 shares of Class A Common Stock at target. The number of shares actually earned and vested upon the achievement of total shareholder return performance criteria measured during a three-year performance period ended on December 15, 2019 was at 95% of target, or 92,339 shares. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 18:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 13,444 | $83.76 | $1,126,073.47 |
DisclosureSEC source: 0001209191-23-009875 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,879 F2 · price: The shares were sold in multiple transactions at prices ranging from $83.67 to $83.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 18:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 17,336 | $83.28 | $1,443,705.67 |
DisclosureSEC source: 0001209191-23-009875 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 65,323 F1 · price: The shares were sold in multiple transactions at prices ranging from $82.67 to $83.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 18:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 30,780 | $45.50 | $1,400,490.00 |
DisclosureSEC source: 0001209191-23-009875 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 82,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 18:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 98,200 | $0.00 Strike: $71.07 | $0.00 |
DisclosureSEC source: 0001209191-23-009875 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 98,200 Underlying: Class A Common Stock · 98,200 shares Expires 2032-12-15 F4 · kind: Effective February 13, 2023 the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. F5 · derivative.exercise_date: This option was granted for a total of 98,200 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2022, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 18:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 98,200 | $0.00 Strike: $71.07 | $0.00 |
DisclosureSEC source: 0001209191-23-009875 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 98,200 shares Expires 2032-12-15 F4 · kind: Effective February 13, 2023 the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. F5 · derivative.exercise_date: This option was granted for a total of 98,200 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2022, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 19, 2022 Filed Dec 19, 2022 21:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 5,082 | $70.80 | $359,805.60 |
DisclosureSEC source: 0001209191-22-062079 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,557 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer in a transaction exempt from Section 16(b) and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units or performance-based restricted stock units. F8 · balance_after: Shares held following reported transactions (i) include 119,557 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest and (ii) exclude 5,168 shares which were issued to and are now held by the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 in connection with the vesting of restricted stock units. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionPerformance-Based Restricted Stock Unit · Derivative | 17,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062079 · doc4.xml · derivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 17,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each performance-based restricted stock unit (PSU) represented a contingent right to receive, upon vesting, one share of Issuer Class A common stock. F12 · derivative.exercise_date: The vesting of the PSU award was dependent upon the achievement of performance criteria measured during a three-year performance period beginning on December 16, 2019 and ending December 13, 2022. The reporting person was eligible to earn from 0% to 200% of the target award amount (which was 21,250 shares) based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. Following the end of the three-year performance period, the Issuer's Compensation Committee certified the achievement of the performance criteria at 80.98% of the target award amount resulting in the vesting of 17,208 PSUs. The remaining 4,042 PSUs were cancelled. F12 · derivative.expiration_date: The vesting of the PSU award was dependent upon the achievement of performance criteria measured during a three-year performance period beginning on December 16, 2019 and ending December 13, 2022. The reporting person was eligible to earn from 0% to 200% of the target award amount (which was 21,250 shares) based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. Following the end of the three-year performance period, the Issuer's Compensation Committee certified the achievement of the performance criteria at 80.98% of the target award amount resulting in the vesting of 17,208 PSUs. The remaining 4,042 PSUs were cancelled. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 13,800 | $71.07 | $980,766.00 |
DisclosureSEC source: 0001209191-22-062079 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,807 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer in a transaction exempt from Section 16(b) and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units or performance-based restricted stock units. F7 · balance_after: Shares held following reported transactions (i) include 129,807 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest and (ii) exclude 5,357 shares which were issued to and are now held by the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 in connection with the vesting of restricted stock units. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 17,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-062079 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each performance-based restricted stock unit (PSU) represented a contingent right to receive, upon vesting, one share of Issuer Class A common stock. F6 · balance_after: Shares held following the reported transactions (i) include 85,886 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest and (ii) exclude 8,676 shares which were issued to and are now held by the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 in connection with the vesting of performance-based restricted stock units. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantEmployee Stock Option (Right to Buy) · Derivative | 98,200 | $0.00 Strike: $71.07 | $0.00 |
DisclosureSEC source: 0001209191-22-062079 · doc4.xml · derivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,200 Underlying: Class A Common Stock · 98,200 shares Expires 2032-12-15 F11 · derivative.exercise_date: This option was granted for a total of 98,200 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2022, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantPerformance-Based Restricted Stock Unit · Derivative | 27,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062079 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,273 Underlying: Class A Common Stock · 27,273 shares Expires not disclosed F10 · derivative.exercise_price: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2022 and ending December 10, 2025. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. F10 · derivative.exercise_date: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2022 and ending December 10, 2025. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. F10 · derivative.expiration_date: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2022 and ending December 10, 2025. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantClass A Common Stock | 54,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062079 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,432 F3 · acquired: Award represents a total of 54,546 restricted stock units granted under the terms of the Issuer's 2020 Stock Plan. Under the terms of the restricted stock unit grant agreement, 1/4 of the total number of units shall vest on each anniversary of December 15, 2022. Each unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon vesting. F4 · balance_after: Shares held following the reported transactions include 140,432 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 10,756 | $73.17 | $787,016.52 |
DisclosureSEC source: 0001209191-22-062079 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,886 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer in a transaction exempt from Section 16(b) and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units or performance-based restricted stock units. F2 · balance_after: Shares held following the reported transaction (i) include 85,886 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest and (ii) exclude 10,937 shares which were issued to and are now held by the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 in connection with the vesting of restricted stock units. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:44 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,688 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-22-046521 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 171,816 Underlying: Class A Common Stock · 16,688 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2014, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:44 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 16,688 | $80.00 | $1,335,040.00 |
DisclosureSEC source: 0001209191-22-046521 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 21,741 Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 21:44 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 16,688 | $42.98 | $717,250.24 |
DisclosureSEC source: 0001209191-22-046521 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 38,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 16:19 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 91,047 | $0.00 Strike: $91.80 | $0.00 |
DisclosureSEC source: 0001209191-22-008850 · doc4.xml · derivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 91,047 Underlying: Class A Common Stock · 91,047 shares Expires 2031-12-15 F1 · kind: Effective February 10, 2022 the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. F2 · derivative.exercise_date: This option was granted for a total of 91,047 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2021, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 16:19 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftEmployee Stock Option (Right to Buy) · Derivative | 91,047 | $0.00 Strike: $91.80 | $0.00 |
DisclosureSEC source: 0001209191-22-008850 · doc4.xml · derivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 91,047 shares Expires 2031-12-15 F1 · kind: Effective February 10, 2022 the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. F2 · derivative.exercise_date: This option was granted for a total of 91,047 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2021, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 20:11 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,453 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-22-003133 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 188,504 Underlying: Class A Common Stock · 29,453 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2014, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 20:11 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 29,453 | $93.10 | $2,741,994.78 |
DisclosureSEC source: 0001209191-22-003133 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 21,741 F2 · price: This transaction was executed in multiple trades at prices ranging from $92.65 to $93.53, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 20:11 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,453 | $42.98 | $1,265,889.94 |
DisclosureSEC source: 0001209191-22-003133 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 20:11 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 5,168 | $93.11 | $481,178.01 |
DisclosureSEC source: 0001209191-22-003133 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 21,741 F1 · price: This transaction was executed in multiple trades at prices ranging from $92.65 to $93.53, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 20:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 3,415 | $91.69 | $313,118.96 |
DisclosureSEC source: 0001209191-21-070707 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 26,909 F4 · price: This transaction was executed in multiple trades at prices ranging from $91.48 to $91.88, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 20:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 1,942 | $90.74 | $176,218.05 |
DisclosureSEC source: 0001209191-21-070707 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 30,324 F3 · price: This transaction was executed in multiple trades at prices ranging from $90.17 to $91.05, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 20:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 5,082 | $92.00 | $467,544.00 |
DisclosureSEC source: 0001209191-21-070707 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,579 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F2 · balance_after: Shares held following the reported transactions include 107,579 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 16, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 5,268 | $91.80 | $483,602.40 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · nonDerivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,829 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F9 · balance_after: Shares held following the reported transactions include 117,829 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 16, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 949 | $91.96 | $87,266.81 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · nonDerivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 21,741 F8 · price: This transaction was executed in multiple trades at prices ranging from $91.81 to $92.15, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.